Frontiers in Cardiovascular Medicine (Jan 2024)

The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

  • Chad Gier,
  • Ian Gilchrist,
  • Matthew Fordham,
  • Luke Riordan,
  • Ella Milchan,
  • Nidhi Patel,
  • Azad Mojahedi,
  • Sahana Choudhury,
  • Tara Kits,
  • Regina Cohen,
  • Joseph Doughtery,
  • John P. Reilly,
  • Andreas Kalogeropoulos,
  • Tahmid Rahman,
  • On Chen

DOI
https://doi.org/10.3389/fcvm.2024.1284562
Journal volume & issue
Vol. 11

Abstract

Read online

Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). There has been a significant improvement in the treatment of dyslipidemia in the past 10 years with the development of new pharmacotherapies. The intent of this review is help enhance clinicians understanding of non-statin lipid lowering therapies in accordance with the 2022 American College of Cardiology Expert Consensus Clinical Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering. We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.

Keywords